



Published in final edited form as:

J Pept Sci. 2010 August ; 16(8): 375–382. doi:10.1002/psc.1249.

Characterization of ConantokinRI-A: Molecular Phylogeny as Structure/Function Study[#]

Konkallu H. Gowd^{a,*}, Maren Watkins^a, Vernon D. Twede^a, Grzegorz W. Bulaj^b, and Baldomero M. Olivera^a

^aDepartment of Biology, University of Utah, Salt Lake City, Utah 84112

^bDepartment of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 84112

Abstract

A multidisciplinary strategy for discovery of new *Conus* venom peptides combines molecular genetics and phylogenetics with peptide chemistry and neuropharmacology. Here we describe application of this approach to the conantokin family of conopeptides targeting NMDA receptors. A new conantokin from *Conus rolani*, ConRI-A, was identified using molecular phylogeny and subsequently synthesized and functionally characterized. ConRI-A is a 24-residue peptide containing three gamma-carboxyglutamic acid residues with a number of unique sequence features compared to conantokins previously characterized. The HPLC elution of ConRI-A suggested that this peptide exists as two distinct, slowly exchanging conformers. ConRI-A is predominantly helical (estimated helicity of 50%), both in the presence and absence of Ca⁺⁺. The order of potency for blocking the four NMDA receptor subtypes by ConRI-A was NR2B>NR2D>NR2A>NR2C. This peptide has a greater discrimination between NR2B and NR2C than any other ligand reported so far. In summary, ConRI-A is a new member of the conantokin family that expands our understanding of structure/function of this group of peptidic ligands targeted to NMDA receptors. Thus, incorporating phylogeny in the discovery of novel ligands for the given family of ion channels or receptors is an efficient means of exploring the megadiverse group of peptides from genus *Conus*.

Keywords

Conantokin; Molecular phylogeny; Conformational interconversion; Helical peptide; Electrophysiology

INTRODUCTION

The conantokins are a family of peptides found in *Conus* venoms that are antagonists of N-methyl D-aspartate (NMDA) receptors [1-3]. Nine conantokin peptides from seven *Conus* species have been documented in the literature: Conantokin-G (ConG) from *Conus geographus* [4], ConT from *Conus tulipa* [5], ConR from *Conus radiatus* [6], ConL from

[#]This work was supported by the grant GM48677 from the National Institute of General Medical Sciences

* Address Correspondence to: Konkallu Hanumae Gowd, Department of Biology, University of Utah, Salt Lake City, Utah 84112; Tel: (801)581-8370. Fax: (801)585-5010, gowd@biology.utah.edu.

Conus lynceus [7], ConPr-A, Pr-B, Pr-C from *Conus parius* [8], ConP from *Conus purpurascens* [9] and ConBr from *Conus brethinghami* [10]. These peptides comprise the only group of peptidic ligands from animal venoms presently known to target NMDA receptors.

We have recently used a multidisciplinary strategy for discovery from *Conus* venoms; the general approach combines peptide chemistry (or recombinant expression), molecular genetics and phylogenetics [11-12]. This approach has been used successfully for developing ligands targeted to various nicotinic receptors, resulting in the availability of selective pharmacological agents for diverse molecular isoforms of the nicotinic receptor family [13]. This general approach has not previously been systematically applied to the conantokin family. In this report, we have initiated the concerted discovery strategy for identifying novel conantokin peptides that can more efficiently allow us to assess structure/function relationships in these peptides.

A recently characterized conantokin peptide, ConBr from *Conus brethinghami*, had a number of divergent characteristics compared to previously described conantokins [10]. We used a phylogenetic approach to find related natural peptides; our goal was a broad assessment of the sequence elements in ConBr that confer its particular selectivity profile. Because *Conus rolani*, a species not previously investigated, is a member of the same clade as *Conus brethinghami*, we obtained the sequence of a conantokin peptide from *Conus rolani* with homology to ConBr, which we designate ConRI-A. The characterization of ConRI-A, and a comparison to ConBr is detailed below. These studies illustrate that molecular phylogeny can be used to quickly identify *Conus* species that have evolved conantokin peptides useful for targeted structure/function insights. We also describe an unexpected and novel conformational property of ConRI-A that emerged from its characterization.

EXPERIMENTAL PROCEDURES

Phylogenetic analysis

Phylogenetic analysis was performed using combined sequences of 12S, 16S and COI mitochondrial gene regions for each species, as previously described [14]. The lengths of the sequences used for analysis were 585-590, 546-548, and 594-709 base pairs for 12S, 16S, and COI, respectively. The sequences were aligned and neighbor-joining trees generated using ClustalX version 2.0.9 [15] with standard default options.

Preparation of genomic DNA and characterization of clones encoding ConRI-A

Genomic DNA was prepared from 20 mg *Conus rolani* tissue using the Genra PUREGENE DNA Isolation **Kit** (Genra Systems, Minneapolis, MN) according to the manufacturer's standard protocol. 10 ng of *C. rolani* genomic DNA was used as a template for polymerase chain reaction (PCR) with oligonucleotides corresponding to conserved regions of the signal sequence (5' GCG ATG CAA CTG TAC ACG TAT CTG) and 3' UTR sequence (5' AAT AAA CAT GAA AGA TTT GGG GAA) of conantokin prepropeptides. The resulting PCR product was purified using the High Pure PCR Product Purification Kit (Roche Diagnostics, Indianapolis, IN) following the manufacturer's suggested protocol. The eluted DNA

fragment was annealed to pNEB206A vector using the USER Friendly Cloning kit (New England BioLabs, Inc., Beverly, MA) following manufacturer's suggested protocol and the resulting product transformed into DH5a competent cells. The nucleic acid sequences of the resulting conantokin toxin-encoding clones were determined according to the standard protocol for Automated sequencing.

Peptide Synthesis

ConRI-A was synthesized using standard Fmoc (N-(9-fluorenyl) methoxycarbonyl) protected amino acids on ABI model 430A peptide synthesizer at the DNA/Peptide Core Synthesis Facility, University of Utah. The side chains of Asp, Glu and Thr residues were protected with tBu group (Novabiochem). The side chains of Lys, Gln and Arg residues were protected with Boc, Trt and Pbf groups (Novabiochem), respectively. The side chains of Gla were protected with tBu groups (Chem-Impex International, Inc.). The peptide was constructed on proline containing preloaded resin, H-Pro-2-CITrt resin (Novabiochem), using standard DCC/HOBT chemistry. The peptide was cleaved from the resin and simultaneous deprotection of side chains was achieved by agitating 20 mg of the resin in 1 ml of reagent K {TFA/phenol/thioanisole/water/ethanedithiol (82.5:5:5:2.5)} at room temperature. The mixture was filtered, precipitated using methyl-*tert*-butyl ether (MTBE) and spun by centrifugation. The pellet was repeatedly washed with cold MTBE and purified over a Vydac C₁₈ column (10 mm × 250 mm, 5 μm particle size) using ACN/H₂O/TFA solvent system. The flow rate was maintained at 3 ml min⁻¹ following a linear gradient of 10–40% ACN over 40 min and the fractions were detected at 220 nm. The purity of conRI-A was confirmed using mass spectrometry. Mass spectra were obtained using a Micromass Quattro II mass spectrometer at the Mass Spectrometry and Proteomics Core Facility of the University of Utah.

Peptide conformation analysis

Conformational analysis of the peptide was achieved using C₁₈ analytical RP-HPLC over the range of temperature from 4–45°C. The desired temperature of the column was achieved by keeping it in a water bath over a period of time. Five nmoles of peptide was dissolved in 50% ACN containing 0.01% TFA and incubated at room temperature for 5 min before injecting to HPLC. The peptide was eluted using a linear gradient of 20–50% Buffer B (90% ACN containing 0.1% TFA) over 35 min. Early-eluting fraction and late-eluting fractions were separated and incubated at 4°C prior to the re-application to column. Distinct fractions were separately ran again under identical chromatographic conditions. Area under early and late eluting conformers was obtained by integrating the chromatograms using data analysis software provided by the manufacturer (Waters Millennium).

Circular Dichroism Spectroscopy

Far-UV CD spectra were recorded with an AVIV Model 62D spectropolarimeter, using a bandwidth of 1 nm, a step size of 1 nM, and an average time of 0.5 sec. Peptide was dissolved in 10 mM HEPES buffer, pH 7.0, with or without 2 mM CaCl₂. All measurements were taken at room temperature, over 250–190 nm wavelength range, using cell of 0.1 cm path length. Peptide concentration was 100 μM, as determined by the absorbance at 280 nm.

Five independent spectra were collected and averaged for each sample. The contribution of buffer to the CD signal was eliminated by subtracting the peptide CD signal with that of the buffer alone CD signal. All spectral intensities were expressed as mean residue ellipticities using the equation reported elsewhere [8]. Molar ellipticity of $-35086.66 \text{ degrees cm}^2 \text{ dmol}^{-1}$ was estimated to be a perfect α -helix (100% α -helix). The percent helical conformation was calculated by assuming a linear relationship in comparison with 100% α -helix.

Heterologous expression of NMDA receptors in *Xenopus* oocytes

The rat NMDA receptor clones used were NR2A, NR2B, NR2C, NR2D, and NR1-2b; GenBank numbers AF001423, U11419, U08259, U08260, and U08264, respectively. We previously used the NR1-3b splice variant to express recombinant NMDA receptors [8-10]; in the present study, we have used NR1-2b splice variant due to its robust expression in the central nervous system [16]. To confirm this splice variant difference does not affect the potency or order of conantokin selectivity toward NMDA receptor complexes, we also assayed conantokins for potency on differing combinations of NR2(A-D) and NR1-3b, and found no difference between splice variants (data not shown). All of the expression clones were driven by a T7 promoter and were used to make capped RNA (cRNA) for injection into the oocytes of *Xenopus laevis* frogs. cRNA was prepared *in-vitro* using Ambion RNA transcription kits (Ambion, Inc.) according to manufacturer's protocols. To express NMDA receptors, 2-5 ng of cRNA for each subunit was injected per oocyte. Oocytes were maintained at 18 degrees Celsius in ND96 solution (96.0 mM NaCl, 2.0 mM KCl, 1.8 mM CaCl₂, 1mM MgCl₂, 5mM HEPES, pH 7.2-7.5) containing antibiotics (septria, amikacin, pen/strep). All voltage-clamp electrophysiology was done using oocytes 1-6 days post-injection.

Two-electrode voltage clamp electrophysiology

All oocytes were voltage clamped at -70mV at room temperature. Oocytes were gravity perfused with Mg^{2+} -free ND96 buffer (96.0 mM NaCl, 2.0 mM KCl, 1.8 mM CaCl₂, 5 mM HEPES, pH 7.2-7.5). Mg^{2+} was not included in the ND96 buffer because Mg^{2+} blocks NMDA receptors at the voltage potential used to clamp oocytes (-70mV). To reduce nonspecific absorption of peptide, bovine serum albumin (BSA) was added to ND96 buffer at a final concentration of 0.1mg/ml. To elicit current from oocytes expressing NMDA receptors, one-second pulses of gravity-perfused agonist solution were administered at intervals of 60s, 90s, or 120s, depending on the rate of receptor recovery from desensitization. Agonist solution was comprised of glutamate and co-agonist glycine suspended in Mg^{2+} -free ND96 buffer at final concentrations of 200 μM and 20 μM , respectively. Buffer was perfused continuously over the oocytes between agonist pulses, except during equilibration periods. During equilibration period, buffer flow was halted for 5 minutes to create a static bath for application of either peptide (suspended in ND96 buffer at various concentrations), or control solution (ND96 buffer alone). The length of equilibration period was equal to or greater than the time necessary to achieve maximal current inhibition at a given concentration. The effect of a peptide on NMDA receptor-mediated current was determined by measuring the amplitude of the first agonist-elicited current pulse immediately following the equilibration period as a percentage of the

amplitude of the baseline current (agonist-elicited current immediately preceding equilibration period). Data acquisition was automated by a virtual instrument made by Doju Yoshikami of the University of Utah. Concentration-response curves were generated using Prism software (GraphPad Software, Inc.), using the following equation, where nH is the Hill coefficient and IC_{50} is the concentration of peptide causing half-maximal block: % Response = $100 / \{1 + ([peptide] / IC_{50})^{nH}\}$.

RESULTS

Phylogenetic analysis

Conus bretinghami is a member of the so-called *Conus sulcatus* complex, a set of deep-water *Conus* species all believed to belong to the *Asprella* clade, with *Conus sulcatus* as the type species (*Asprella* is regarded as a subgenus of *Conus* in most, but not all, taxonomic works). One species in this branch of *Conus* is *Conus rolani*; since we had collected this species, genomic DNA clones from *Conus rolani* were analyzed. *C. rolani* is also a deep-water piscivorous cone snail collected from the Philippine's coast using tangle nets (ref)". The phylogenetic relationship of *Conus rolani* to *Conus bretinghami*, the source of ConBr, was determined by analysis of the combined sequences of 12s, 16s and COI mitochondrial gene regions and is shown in Figure 1; all *Conus* species that have yielded other conantokin sequences are shown in the figure.

Analysis of a clone encoding ConRI-A from *Conus rolani*

Prior work on α -conopeptides targeted to nicotinic acetylcholine receptors revealed that the analysis of *Conus* species closely related to each other has potential for identifying homologous peptides with a sufficient level of amino acid sequence divergence to gain structure/function insights. ConBr, a conantokin peptide from *Conus bretinghami* had some intriguing functional features; to assess structure/function relationships for ConBr, we wanted to identify a homologous peptide with significant amino acid sequence differences.

A *C. rolani* clone encoding a peptide precursor with a high degree of homology to previously identified conantokin precursors was identified and designated ConRI-A. The sequences of the predicted corresponding open reading frames of ConRI-A and ConBr precursors are shown in Figure 2. The striking similarity of the sequences encoding ConRI-A and ConBr establishes that ConRI-A is a member of the conantokin superfamily. A notable feature of ConRI-A is that the predicted amino acid at position 1 of the mature peptide (alanine), differs from that of the canonical N-terminal glycine (or aspartate) at position 1 in all previously identified conantokins.

A comparison of the predicted mature sequences of ConRI-A and ConBr after the predicted post-translational modification is shown in Figure 3. In a similar manner to ConBr, the glutamate residues that are known to be γ -carboxylated in members of the conantokin family purified from venom (i.e., glutamates at positions 3-4, and each glu that occurs in a spacing of every 3-4 amino acids thereafter, such that they align on a single side of the helical peptide) are predicted to be post-translationally modified to γ -carboxyglutamate in ConRI-A.

However, the glutamate at position 11, which immediately follows the carboxylglutamate predicted at position 10, is not predicted to undergo post-translational modification.

Characterization of ConRI-A

In order to characterize the deduced conantokin from *C. rolani*, chemical synthesis of the predicted sequence shown in Figure 3 was carried out as described under Methods. The observed mass of the peptide, as revealed from ESI-MS, is 3042.5, 2997.2, 2953.9 and 2909.7. Occurrence of multiple peaks in ESI-MS corresponds to the loss of carboxyl groups, a phenomenon previously observed in Gla containing *Conus* peptides [9, 17].

The elution profile of ConRI-A is unusual with two peaks separated by a broad trough. This apparent chromatographic heterogeneity was assessed by eluting the peptide from the HPLC column at different temperature. Figure 4a shows effect of temperature on chromatography of the peptide. At low (4°C) temperature, ConRI-A yields two well-resolved peaks; as the temperature increases (22°C), the trough between two peaks increases and at high temperature (45°C), a single homogeneous peak is found. These observations clearly suggest that ConRI-A exists as two distinct, slow-exchanging conformers in solution. The broad trough in the chromatogram at 22°C can be attributed to interconversion of the two conformers; at higher temperature, conformational interconversion may be sufficiently rapid that the C₁₈ column cannot resolve the two conformers resulting in a single peak in the elution profile. Under these conditions, the conformational interconversion is presumably faster than the chromatographic resolution.

The conformational equilibrium between two conformers in ConRI-A was probed at 4°C. Figure 4b shows elution profiles of the fractions isolated from the chromatogram of ConRI-A. The early eluting hydrophilic component and late eluting hydrophobic fraction of ConRI-A were separately collected and re-injected onto the column at 4°C. Both components were incubated at 4°C for 20 min prior to re-injection. Re-injection of either of the fraction results in a reappearance of both of the HPLC peaks and a ratio between two peaks of ~ 2.6:1 was obtained in both cases. This observation is consistent with the presence of two interconvertible conformers of ConRI-A in solution, which can be separated upon the appropriate chromatographic conditions at 4°C. Since the ratio of major and minor conformers of ConRI-A is independent of peptide concentration, it is likely that the chromatographic heterogeneity is due to intramolecular changes (and not, for instance, dimerization). For example, proline-containing peptides exhibiting peak-splitting in an RP-HPLC column have been documented in the literature [18-23].

Circular Dichroism Spectroscopy

Specific bands in the far-UV circular dichroism spectra have been widely used for rapid determination of backbone conformation of proteins (or) peptides. Secondary structural information derived from CD spectra can represent qualitatively the overall fold of molecule and such studies have been extensively employed in the characterization of conantokins. Figure 5 shows circular dichroism spectra of ConRI-A. ConRI-A is predominantly alpha helical and estimated helicity is 50%, which is essential same in presence and absence of divalent cation (Ca²⁺). Molecular modeling of homologues ConBr indicates the presence of

helical structure between 2-12 residues of the molecule [10]. ConRI-A contains eight identical residues compared to that of ConBr among structured 2-12 peptide segment. The observed percentage of helicity for ConRI-A and its homology to ConBr strongly suggest that both the peptides may adopt similar helical conformation. Surprisingly ConBr results in a single homogenous peak in RP-HPLC elution profile at room temperature, whereas ConRI-A exhibits pronounced asymmetry.

Functional Characterization of ConRI-A

Due to the high degree of homology of ConRI-A with ConBr (a known antagonist of the NR2B and NR2D NMDA receptor subtypes, [10]), we assessed the functional antagonism of ConRI-A on the four NMDA receptor subtypes with different NR2 subunits (NR2A/NR2D). These were heterologously expressed in *Xenopus* oocytes in combination with the NR1-2b splice variant. Using two-electrode voltage clamp electrophysiology, we determined the function of ConRI-A by applying the peptide to oocytes and allowing for a 5-minute equilibration period in a static bath. The effect of the peptide was measured by normalizing the agonist-elicited response following equilibration period to baseline response in the absence of peptide. Concentration response curves for ConRI-A on each of the four NMDA receptor subtypes is shown in Figure 6. The order of potency for ConRI-A was NR2B>NR2D>NR2A>NR2C. Interestingly, although 9 amino acids differ between the corresponding positions of ConRI-A and ConBr (Figure 3b), the order of NR2 subunit selectivity was identical for the two peptides, and the degree of potency on each subunit was similar (Table 1).

DISCUSSION

We have characterized a novel conantokin, ConRI-A from *Conus rolani*, a *Conus* species that belongs to the *Asprella* clade. We previously characterized ConBr from *Conus bretinghami*, another species in *Asprella*; ConBr had a pharmacological profile for the different NMDA receptor subtypes distinct from previously characterized members of the conantokin family. The rationale for focusing on species in the same clade of *Conus* as *Conus bretinghami* was to gain structure/function insights using a phylogenetic approach (**instead** of, for example, using the standard “alanine walk”). Analysis of a *Conus rolani* library revealed a conantokin peptide that differed in 9 out of 24 amino acids in its primary sequence from ConBr. The conserved sequence features included the Tyr 5 residue previously shown to confer a relatively high affinity for the NR2D subtype [10].

The precursor sequences of ConBr and ConRI-A are typical in the pattern of divergence seen in other conopeptide superfamilies. Thus, the mature toxin sequences are both 24 AA, but the initially translated open reading frame is 103 amino acids. There is a signal sequence of 21 AA that is completely identical in the two predicted precursors. A relatively large propeptide region (58 AA) is found between the signal sequence and the mature conantokin peptide, with a typical proteolytic cleavage site at the C-terminus indicated by the arrow in Figure 2. There are only two divergent AA positions in the 58 amino acid propeptide region (divergence = 3.4%). On the other hand, the very considerable divergence in the mature peptide region (9/24 nonidentical AA; 37.5% divergence) is a characteristic result of the

focal hypermutation of conopeptides that has been repeatedly noted [24-26]. These mature peptide regions are among the most rapidly evolving gene sequences known.

The precursors of γ -carboxylated peptides isolated from *Conus* contain a propeptide sequence that serves as the γ -carboxylase recognition sequence (γ -CRS) for the *Conus* γ -glutamyl carboxylase. In the case of ConG from *Conus geographus*, Bandyopadhyay *et al* [27] demonstrated that the γ -CRS was within the -20 to -1 region of the propeptide sequences within which there are two divergent positions between ConRI-A and conBr. γ -CRS have also been identified in the propeptide regions of other γ -carboxylated peptides e.g. in ϵ TxIX(tx5a) [28- 29] belonging to the T-superfamily and Tx9a [30] in the P-superfamily. The γ -CRS in Gla-TxX and Gla-TxXI is however present as a “post-peptide”.

Since the γ -CRS in peptides belonging to different superfamilies are highly divergent it has not been possible to assign any common sequence features. Czerwiec *et al* [31] pointed out the presence of conserved basic residues, and α -helicity of the propeptide. A structure-function study of ϵ TxIX [32] suggested the importance of hydrophobic residues. Hydrophobic residues are also important in the mammalian γ -CRS [31]. In the case of the γ -CRS from ConG, substitution of the basic residues by alanine did not have any significant effect [33]. However, the roles of hydrophobic residues in the γ -CRS from conantokins have not been investigated. The putative γ -CRS region of ConBr and ConRI-A are highly similar to that of ConG, and all of the large hydrophobic residues are conserved. Thus, we do not expect the amino acid changes between ConBr and ConRI-A, nor between these peptide precursors and the ConG precursors to affect the function of the γ -CRS.

The characterization of ConRI-A resulted in the unexpected discovery that ConRI-A equilibrates between two conformational states. If the temperature is lowered, the equilibration slows down sufficiently to separate the two conformational forms using standard HPLC conditions. Discrete conformational states have not previously been detected in for any conantokin peptide. Most *Conus* peptides appear to have a single solution conformation with some notable exceptions [34-39]. The contryphan family of peptides that have a single disulfide bond as well as a D-amino acid, have two interconverting conformational states, dependent on the presence of the D-amino acid [40]. Another peptide with more than one conformational state in solution is α -conotoxin MI; this peptide equilibrated between the two alternative conformational states relatively slowly [41].

In all these prior cases, the conformational equilibrium was in the context of a small peptide with disulfide bonds. What is novel about the discovery of the conformational equilibration between two states in ConRI-A is that this peptide has no disulfide cross-links at all. Given its sequence homology to ConBr, the presence of two conformers was rather unexpected, since the latter peptide elutes from an HPLC column as a single homogenous peak. At present, the molecular basis of unique chromatographic behavior of ConRI-A is unclear.

There are several noteworthy features of ConRI-A. In ConG, the first conantokin characterized, there were 5 γ -carboxyglutamate residues — a number of studies have established that these are important for giving the peptide its helical structure in solution [42]. As shown in Table 2, there have been a number of conantokin peptides characterized in

which γ -carboxyglutamate residues are substituted with other amino acids. Most notably, the $\gamma 7$ in *ConG* is substituted with a lysine residue, in most of the conantokin peptides characterized so far (this is the case for both *ConBr* and *ConRI-A*). The literature to date suggests that in conantokins such as *ConG* with a γ -carboxyglutamate at residue 7, Ca^{++} is required to maintain the helical conformation [43]; however, the presence of lysine at this position confers stability to the helical conformation, even in the absence of Ca^{++} , as we have demonstrated for *ConRI-A* using circular dichroism. We note that *ConRI-A* is the only conantokin peptide characterized so far in which two of the 5 Glu residues in *ConG* are substituted by Lys; the presence of Lys14 was only found in *ConPrB*; however, in this peptide, position 7 has Glu rather than Lys.

Another unusual feature of *ConRI-A* is that it is the first native conantokin sequence characterized with alanine at position 1. Previous mutational studies of *ConG*, *ConT* and *ConR* indicated that an Ala substitution for glycine at position 1 resulted in an ~10-fold reduction in potency [44-46]. However, since the potency of *ConRI-A* and *ConBr* do not differ significantly, it would appear that the Ala substitution for Gly in these peptides from *Conus* species in the *Asprella* clade is not as functionally significant as was found for the other conantokin peptides, suggesting that there are sequence features of these peptides that allow a substitution at position 1 to be more readily tolerated with respect to its functional activity.

Although the mature *ConBr* and *ConRI-A* sequences diverge significantly from each other (37.5% divergence) they are nevertheless much more similar to each other than either peptide is to any other conantokin sequences that have been identified so far (see Table 2). Indeed, the sequence identity of peptides that come from *Conus* species in the same clade (43%) is generally greater than is found for two conantokin sequences from species that come from different clades (20-25% sequence identity is typical). It is for this reason that a systematic comparison of conantokin sequences from species within a clade is equivalent to a detailed mutational study of a particular peptide, since such a phylogenetically-informed analysis has the potential to reveal which amino acid sequences are stringently conserved, and for which substitutions are acceptable in sets of peptides that may have homologous physiological functions.

The comparison of the sequences of *ConBr* and *ConRI-A*, shown in Figure 3 reveals that 15 of the 24 amino acids are identical, but there are 9 substitutions. Three of these (Ala1, Lys17, and Thr21) are conservative substitutions with the other 5 non conservative. Correlating the sequence changes with the functional characterization of *ConRI-A* suggests that at these 5 positions, particular AA are not stringently required for either potency nor selectivity, since the functional activities of *ConBr* and *ConRI-A* are similar (see Table 1). It seems reasonable to regard them as functionally homologous venom components of two different *Conus* species, given the similarities in potency and selectivity for the 4 different subtypes of NMDA receptors. One of the conserved residues, Tyr 5 was previously shown to be critical for an unusual pharmacological characteristic of these peptides: compared to other conantokins, these peptides exhibit a relatively high affinity for the NR2D receptor subtype [10].

Although the shift in affinity from ConBr is modest, the increase in affinity for NR2B and decrease in NR2C affinity gives the peptide a 55-fold preference for NR2B over NR2C, the greatest discrimination yet found among conantokins for these two NMDA receptor subtypes. This makes ConRI-A a potentially useful pharmacological tool for B/C differentiation.

Acknowledgments

We thank Drs. Robert Schackmann and Scott Endicott from the DNA/Peptide Synthesis Core Facility at the University of Utah for the synthesis of peptides. Gowd KH acknowledges Pradip K. Bandyopadhyay and Russell W. Teichert for useful scientific discussions.

ABBREVIATIONS

CD spectroscopy	Circular Dichroism spectroscopy
ConRI-A	ConantokinRI-A
Gla, γ	γ -carboxyglutamate
NMDA	N-methyl-D-aspartate
RP-HPLC	Reverse-Phase High Performance Liquid Chromatography

REFERENCES

1. Layer RT, Wagstaff JD, White HS. Conantokins: peptide antagonists of NMDA receptors. *Curr Med Chem.* 2004; 11:3073–3084.
2. Jimenez EC. Conantokins: from “sleeper” activity to drug development. *Philippine Science Letters.* 2009 (in press).
3. Twede VD, Miljanich G, Olivera BM, Bulaj G. Neuroprotective and cardioprotective conopeptides: an emerging class of drug leads. *Curr Opin Drug Discov Devel.* 2009; 12:231–239.
4. Mena EE, Gullak MF, Pagnozzi MJ, Richter KE, Rivier J, Cruz LJ, Olivera BM. Conantokin-G: a novel peptide antagonist to the N-methyl-D-aspartic acid (NMDA) receptor. *Neurosci. Lett.* 1990; 118:241–244. [PubMed: 2177176]
5. Haack JA, Rivier J, Parks TN, Mena EE, Cruz LJ, Olivera BM. Conantokin-T. A gamma-carboxyglutamate containing peptide with N-methyl-d-aspartate antagonist activity. *J. Biol. Chem.* 1990; 265:6025–6029. [PubMed: 2180939]
6. White HS, McCabe RT, Armstrong H, Donevan SD, Cruz LJ, Abogadie FC, Torres J, Rivier JE, Paarmann I, Hollmann M, Olivera BM. In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail *Conus radiatus*. *J. Pharmacol. Exp. Ther.* 2000; 292:425–432. [PubMed: 10604979]
7. Jimenez EC, Donevan S, Walker C, Zhou LM, Nielsen J, Cruz LJ, Armstrong H, White HS, Olivera BM. Conantokin-L, a new NMDA receptor antagonist: determinants for anticonvulsant potency. *Epilepsy Res.* 2002; 51:73–80. [PubMed: 12350383]
8. Teichert RW, Jimenez EC, Twede V, Watkins M, Hollmann M, Bulaj G, Olivera BM. Novel Conantokins from *Conus parius* Venom are specific antagonists of N-Methyl-D-aspartate receptors. *J. Biol. Chem.* 2007; 282:36905–36113. [PubMed: 17962189]
9. Gowd KH, Twede V, Watkins M, Krishnan KS, Teichert RW, Bulaj G, Olivera BM. Conantokin-P, an unusual conantokin with a long disulfide loop. *Toxicon.* 2008; 52:203–213. [PubMed: 18586049]
10. Twede VD, Teichert RW, Walker CS, Gruszczynski P, Kamierniewicz R, Bulaj G, Olivera BM. Conantokin-Br from *Conus bretinghami* and selectivity determinants for the NR2D subunit of the NMDA receptor. *Biochemistry.* 2009; 48:4063–4073. [PubMed: 19309162]

11. Olivera BM. *Conus* peptides: biodiversity-based discovery and exogenomics. *J Biol Chem.* 2006; 281:31173–31177. [PubMed: 16905531]
12. Olivera BM, Teichert RW. Diversity of the neurotoxic *Conus* peptides: a model for concerted pharmacological discovery. *Mol Interv.* 2007; 7:251–260. [PubMed: 17932414]
13. Olivera BM, Quik M, Vincler M, McIntosh JM. Subtype-selective conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical applications. *Channels (Austin).* 2008; 2:143–152. [PubMed: 18849660]
14. Nam HH, Showers-Corneli P, Watkins M, Olivera BM, Bandyopadhyay P. Multiple genes elucidate the evolution of venomous snail-hunting *Conus* species. *Molecular Phylogenetics and Evolution.* 2009; 53:645–652. [PubMed: 19616106]
15. Larkin G, Blackshields NP, Brown 3R, Chenna PA, McGettigan H, McWilliam F, Valentin IMWallace A, Wilm R, Lopez JD, Thompson TJ, Gibson, Higgins DG. Clustal W and Clustal X version 2.0. *Bioinformatics Applications Note.* 2007; 23:2947–2948.
16. Laurie DJ, Seeburg PH. Regional and developmental heterogeneity in splicing of the rat brain NMDAR1 mRNA. *J Neurosci.* 1994; 14:3180–3194. [PubMed: 8182465]
17. Jakubowski JA, Keays DA, Kelley WP, Sandall DW, Bingham JP, Livett BG, Gayler KR, Sweedler JV. Determining sequences and post-translational modifications of novel conotoxins in *Conus victoriae* using cDNA sequencing and mass spectrometry. *J Mass Spectrom.* 2004; 39:548–557. [PubMed: 15170751]
18. Gesquiere JC, Diesis E, Cung MT, Tartar A. Slow isomerization of some proline-containing peptides inducing peak splitting during reversed-phase high performance liquid chromatography. *J. Chromatogr.* 1989; 478:121–129.
19. Trabelsi H, Bouabdallah S, Sabbah S, Raouafi F, Bouzouita K. Study of the cis-trans isomerization of enalapril by reversed-phase liquid chromatography. *J Chromatogr A.* 2000; 871:189–199. [PubMed: 10735299]
20. O'Neal KD, Chari MV, McDonald CH, Cook RG, Yu-Lee LY, Morrisett JD, Shearer WT. Multiple cis-trans conformers of the prolactin receptor proline-rich motif (PRM) peptide detected by reverse-phase HPLC, CD and NMR spectroscopy. *Biochem J.* 1996; 315:833–844. [PubMed: 8645165]
21. Francart C, Wieruszkeski JM, Tartar A, Lippens G. Structural and dynamic characterization of Pro Cis/Trans Isomerization in a small cyclic peptide. *J. Am. Chem. Soc.* 1996; 118:7019–7027.
22. Shi T, Spain SM, Rabenstein DL. A striking periodicity of the cis/trans isomerization of proline imide bonds in cyclic disulfide-bridged peptides. *Angew. Chem. Int. Ed.* 2006; 45:1780–1783.
23. Jacobsen R, Jimenez EC, Grilley M, Watkins M, Hillyard D, Cruz LJ, Olivera BM. The contryphans, a D-tryptophan-containing family of *Conus* peptides: interconversion between conformers. *J. Pept. Res.* 1998; 51:173–179. [PubMed: 9531419]
24. Espiritu DJ, Watkins M, Dia-Monje V, Cartier GE, Cruz LJ, Olivera BM. Venomous cone snails: molecular phylogeny and the generation of toxin diversity. *Toxicon.* 2001; 39:1899–1916. [PubMed: 11600154]
25. Olivera BM, Walker C, Cartier GE, Hooper D, Santos AD, Schoenfeld R, Shetty R, Watkins M, Bandyopadhyay P, Hillyard DR. Speciation of cone snails and interspecific hyperdivergence of their venom peptides. Potential evolutionary significance of introns. *Ann. N Y. Acad. Sci.* 1999; 870:223–237. [PubMed: 10415486]
26. Duda TF Jr, Palumbi SR. Molecular genetics of ecological diversification: duplication and rapid evolution of toxin genes of the venomous gastropod *Conus*. *Proc Natl Acad Sci U S A.* 1999; 96:6820–6823. [PubMed: 10359796]
27. Bandyopadhyay PK, Colledge CJ, Walker CS, Zhou LM, Hillyard DR, Olivera BM. Conantokin-G precursor and its role in gamma-carboxylation by a vitamin K-dependent carboxylase from a *Conus* snail. *J. Biol. Chem.* 1998; 273:5447–5450. [PubMed: 9488665]
28. Rigby AC, Lucas-Meunier E, Kalume DE, Czerwiec E, Hambe B, Dahlqvist I, Fossier P, Baux G, Roepstorff P, Baleja JD, Furie BC, Furie B, Stenflo J. A conotoxin from *Conus textile* with unusual posttranslational modifications reduces presynaptic Ca²⁺ influx. *Proc Natl Acad Sci U S A.* 1999; 96:5758–5763. [PubMed: 10318957]

29. Walker CS, Steel D, Jacobsen RB, Liraz MB, Cruz LJ, Hooper D, Shetty R, DelaCruz RC, Nielsen JS, Zhou LM, Bandyopadhyay P, Craig AG, Olivera BM. The T-superfamily of conotoxins. *J Biol Chem.* 1999; 274:30664–30671. [PubMed: 10521453]
30. Liraz MB, Hooper D, Corpuz GP, Ramilo CA, Bandyopadhyay P, Cruz LJ, Olivera BM. The spasmodic peptide defines a new conotoxin superfamily. *Biochemistry.* 2000; 39:1583–1588. [PubMed: 10677206]
31. Czerwiec E, Kalume DE, Roepstorff P, Hambe B, Furie B, Furie BC, Stenflo J. Novel gamma-carboxyglutamic acid-containing peptides from the venom of *Conus textile*. *FEBS J.* 2006; 273:2779–2788. [PubMed: 16817904]
32. Bush KA, Stenflo J, Roth DA, Czerwiec E, Harrist A, Begley GS, Furie BC, Furie B. Hydrophobic amino acids define the carboxylation recognition site in the precursor of the gamma-carboxyglutamic-acid-containing conotoxin epsilon-TxIX from the marine cone snail *Conus textile*. *Biochemistry.* 1999; 38:14660–14666. [PubMed: 10545191]
33. Huber P, Schmitz T, Griffin J, Jacobs M, Walsh C, Furie B, Furie BC. Identification of amino acids in the gamma-carboxylation recognition site on the propeptide of prothrombin. *J Biol Chem.* 1990; 265:12467–12473. [PubMed: 2373701]
34. Jimenez EC, Olivera BM, Gray WR, Cruz LJ. Contryphan is a D - tryptophan containing *Conus* peptide. *J. Biol. Chem.* 1996; 271:28002–28005. [PubMed: 8910408]
35. Jimenez EC, Craig AG, Watkins M, Hillyard DR, Gray WR, Gulyas J, Rivier JE, Cruz LJ, Olivera BM. Bromocontryphan: Post-translational bromination of tryptophan. *Biochemistry.* 1997; 36:989–994. [PubMed: 9033387]
36. Jimenez EC, Watkins M, Juszczak LJ, Cruz LJ, Olivera BM. Contryphans from *Conus textile* venom ducts. *Toxicon.* 2001; 39:803–808. [PubMed: 11137539]
37. Massilia GR, Schinina ME, Ascenzi P, Politicelli F. Contryphan-Vn: A novel peptide from the venom of the Mediterranean snail *Conus ventricosus*. *Biochem. Biophys. Res. Commun.* 2001; 288:908–913. [PubMed: 11688995]
38. Hanumae Gowd K, Sabareesh V, Sudarslal S, Iengar P, Franklin B, Fernando A, Dewan K, Ramaswami M, Sarma SP, Sikdar SK, Balaram P, Krishnan KS. Novel peptides of therapeutic promise from Indian Conidae. *Ann. N.Y. Acad. Sci.* 2005; 1056:462–473. [PubMed: 16387709]
39. Pallaghy PK, Melnikova AP, Jimenez EC, Olivera BM, Norton RS. Solution structure of contryphan-R, a naturally occurring disulfide-bridged octapeptide containing D-Tryptophan: comparison with protein loops. *Biochemistry.* 1999; 38:11553–11559. [PubMed: 10471307]
40. Jacobsen RB, Jimenez EC, De la Cruz RG, Gray WR, Cruz LJ, Olivera BM. A novel D-leucine-containing *Conus* peptide: diverse conformational dynamics in the contryphan family. *J Pept Res.* 1999; 54:93–99. [PubMed: 10461743]
41. Gray WR, Rivier JE, Galyean R, Cruz LJ, Olivera BM. Conotoxin MI. Disulfide bonding and conformational states. *J Biol Chem.* 1983; 258:12247–12251. [PubMed: 6630187]
42. Prorok M, Castellino FJ. Structure–function relationships of the NMDA receptor antagonist conantokin peptides. *Curr Drug Targets.* 2001; 2:313–322. [PubMed: 11554555]
43. Cnudde SE, Prorok M, Dai Q, Castellino FJ, Geiger JH. The crystal structures of the calcium-bound con-G and con-T[K7gamma] dimeric peptides demonstrate a metal-dependent helix-forming motif. *J Am Chem Soc.* 2007; 129:1586–1593. [PubMed: 17243678]
44. Blandl T, Prorok M, Castellino FJ. NMDA-receptor antagonist requirements in conantokin-G. *FEBS Lett.* 1998; 435:257–262. [PubMed: 9762921]
45. Warder SE, Blandl T, Klein RC, Castellino FJ, Prorok M. Amino acid determinants for NMDA receptor inhibition by conantokin-T. *J Neurochem.* 2001; 77:812–822. [PubMed: 11331410]
46. Blandl T, Zajicek J, Prorok M, Castellino FJ. Sequence requirements for the N-methyl-D-aspartate receptor antagonist activity of conantokin-R. *J Biol Chem.* 2001; 276:7391–7396. [PubMed: 11096077]




Figure 1. Phylogenetic analysis using combined 12S, 16S and COI sequences showing all *Conus* species from which conantokin peptides have been identified. *Conus rolani* was collected from Philippines coast using tangle nets.



Figure 2. Precursor sequences of *ConBr* and *ConRI-A*. The arrows indicate the signal sequence/propeptide and propeptide/mature conantokin boundaries.

(a)

Conantokin	Nucleotide and Predicted Amino Acid Sequences
Conantokin <i>Br</i>	G D E E Y S K F I E R E R E A G R L D L S K F P GGCGATGAAGAATATTCAAAGTTTATAGAGAGAGAACGCGAAGCAGGAAGACTGGATTTGTCAAAATTCCCG
Conantokin <i>Rl-A</i>	A D E E Y L K F I E E Q R K Q G K L D P T K F P GCCGATGAAGAATATTTAAAGTTTATAGAGGAACAACGCAAACAAGGAAAACCTGGATCCGACAAAATTCCCG

(b)

5 10 15 20

Conantokin*Rl-A* : AD γ YLKFI γ EQRKQGLDPTKFP

Conantokin*Br* : GD γ YSKFI γ RER γ AGRDL SKFP

Figure 3.

cDNA sequences encoding conantokins. (a) Nucleotide and predicted amino acid sequences for Con*Rl-A* and Con*Br*. (b) Predicted mature peptides. Posttranslational modifications (γ : Gla) were assumed based on consistent occurrence of Gla in naturally isolated conantokins and amino acid spacing between Gla residues.




Figure 4. Conformational analysis of ConRI-A using RP-HPLC. (a) Effect of temperature on chromatography of the peptide at indicated temperature. The temperature of the C₁₈ analytical column was maintained either by incubating in ice (or) water bath of the desired temperature. (b) Elution profiles obtained by reinjection of the fractions corresponding to Peak-1 and Peak-2 of the peptide at 4°C. Both major and minor conformers are represented from each peak.




Figure 5. Circular dichroism spectra of ConRI-A. Spectra were recorded by dissolving peptide in 10 mM HEPES buffer at pH 7.0, containing either 2 mM CaCl₂ (or) absence of CaCl₂. Shown is an average spectra obtained from five independent scans. Percentage of helicity of peptide in the presence (or) absence of calcium was found to be 50%.




Figure 6. Concentration-response curve of ConRI-A on the four different NR2 NMDA receptor subunits separately co-expressed with NR1-2b in *Xenopus* oocytes. Each data point represents the response obtained from three independent oocytes. Curve fitting was performed using Prism software (GraphPad Software, Inc.).

Table 1Comparison of Approximate IC₅₀ (μM) values of ConRI-A and ConBr.

Peptide	NMDA receptor subtypes NR2(A-D)			
	NR2A IC ₅₀	NR2B IC ₅₀	NR2C IC ₅₀	NR2D IC ₅₀
ConBr	0.68	0.14	4.9	0.31
ConRI-A	2.1	0.11	6.1	0.48

Table 2

Comparison of known conantokin sequences

<i>Conus</i> Clade	Conantokin	Peptide Sequence	Reference
<i>Gastroidium</i>	ConT	GE $\gamma\gamma$ YQK ML γ NLR γ AEVK KNA *	[5]
	ConG	GE $\gamma\gamma$ LQ γ NQ γ LIR γ KSN *	[4]
<i>Phasmoconus</i>	ConL	GE $\gamma\gamma$ VAK MAA γ LAR γ DAVN *	[7]
	ConR	GE $\gamma\gamma$ VAK MAA γ LAR γ NIAK GCKVNCYP ^	[6]
	ConPr-A	GED γ YA γ GIR γ YQLI HGK I ^	[8]
	ConPr-B	DEO γ YA γ AIR γ YQLK YGK I ^	[8]
	ConPr-C	GEO γ VAK WA γ GLR γ KAASN *	[8]
<i>Chelyconus</i>	ConP	GE $\gamma\gamma$ HSK YQ γ CLR γ IRVNK VQQ γ C ^	[9]
<i>Asprella</i>	ConBr	GD $\gamma\gamma$ YSK FI γ RER γ AGR LDLSKFP ^	[10]
	ConRI-A	AD$\gamma\gamma$ YLK FIγ EQRK QGK LDPTKFP ^	This work

Con, conantokin; γ , γ -carboxyglutamate; O, 4-*trans*-hydroxyproline

* C-terminal amidation

^ C-terminal free acid.